Eligibilidad (mes)	Régimen de platino	Número de paciente	Comparación	Comentarios sobre resultados (mes)
SG = supervivencia general; SSE = supervivencia sin evolución;
Sensible al platino (>6)	Carboplatino + doxorrubicina pegilada-liposomal	104	Ninguna	mediana de SSE 9; mediana de SG 31 [2]
Sensitivo al platino (>6)	Carboplatino + epirubicina	190	Carboplatino	Potenciado para la diferencia de respuestas; SG 17 vs. 15 [3]
Sensitivo al platino (≥12)	Cisplatino + doxorrubicina + ciclofosfamida	97	Paclitaxel	SSE 15,7 vs. 9; SG 34,7 vs. 25,8 [4]
Sensitivo al platino (>6)	Carboplatino + gemcitabina	356	Carboplatino	SSE 8,6 vs. 5,8*; SG 18 vs. 17 [5]
Sensitivo al platino (>6)	Cisplatino o carboplatino + paclitaxel	802	Solo o nontaxano + platinos	SSE 11 vs. 9; SG 24 vs. 19 [6]

Bibliografía

2. Ferrero JM, Weber B, Geay JF, et al.: Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2): 263-8, 2007.  [PUBMED Abstract]
   
   
3. Bolis G, Scarfone G, Giardina G, et al.: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81 (1): 3-9, 2001.  [PUBMED Abstract]
   
   
4. Cantù MG, Buda A, Parma G, et al.: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (5): 1232-7, 2002.  [PUBMED Abstract]
   
   
5. Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (29): 4699-707, 2006.  [PUBMED Abstract]
   
   
6. Parmar MK, Ledermann JA, Colombo N, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (9375): 2099-106, 2003.  [PUBMED Abstract]